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Abstract 
This review paper describes innovative methods and technology for non-invasive human brain physiological monitoring based 
on measuring the acoustic properties of the brain parenchyma. The clinical investigation of new technology shows the similarity 
between the invasively recorded intracranial pressure (ICP) and non-invasively recorded intracranial blood volume (IBV) pulse waves, 
slow waves and slow trends under intensive care unit (ICU) conditions. Also, the applicability of the non-invasive IBV slow wave 
monitoring technique for long-term non-invasive cerebrovascular autoregulation monitoring is supported by theoretical and 
experimental studies.  The paper also describes a new absolute ICP measurement method which does not need calibration. The new 
method is based on a two-insonation depth transcranial Doppler (TCD) technique for absolute ICP and external absolute pressure aPe 
comparison using the eye artery (EA) as a natural ‘‘scales’’. The clinical study shows that it is possible to measure ICP non-invasively 
without calibration of the system. 
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Introduction 
The primary clinical objective after traumatic brain 
injury (TBI) is to prevent secondary insults including 
elevated ICP, a common sequel to the primary injury. The 
concept is to prevent cerebral hypoxia by maintaining 
sufficient oxygen delivery to the intracranial neural tissues. 
This implies that cerebral blood flow (CBF), arterial 
oxygen saturation and hemoglobin concentration in a 
specific patient need to be adequate.  
Intracranial pressure (ICP) and cerebral perfusion 
pressure (CPP) monitoring is recommended for severe 
TBI. There are several limitations of ICP and CPP 
monitoring: the ICP devices are invasive, discint ICP and 
CPP target recommendations are uncertain and not specific 
for the individual patient, CPP is not equivalent to CBF 
and the relationship between CBF and CPP depends on the 
status of CBF autoregulation.  
Additional causes of elevated ICP include shaken-baby 
syndrome, epidural and subdural hematomas, brain 
hemorrhage, meningitis, encephalitis, lead poisoning, 
Reye‘s syndrome, hypervitaminosis A, diabetic 
ketoacidosis, water intoxication, brain tumors, blood clots 
in the craniocavity, abcesses, stroke, hydrocephalus and 
dural synus and venous thrombosis. Elevated ICP is very 
serious pathology and may be life threatening. It require 
immediate treatment and continuous monitoring.  
This review paper describes innovative methods and 
technology for human brain non-invasive physiological 
monitoring. The non-invasive methods of brain 
physiological monitoring and the prototype devices have 
been developed by the “Vittamed technologijos” team. 
This presented study is the implementation of the project, 
“Technological development and applied research of 
complex equipment and innovative non-invasive methods 
of human brain physiological monitoring” (BPD04-ERPF-
3.1.7-03-05/0020), funded by EU structural funds as per 
the Scientific Research and Development activity area 
(applied research and technological development of 
Measure 3.1, Direct Support for Business). The need for 
this project was determined by worldwide demand for 
physiological measuring equipment that would monitor the 
human brain non-invasively. Currently such equipment is 
not available in a clinical practice. The clinical 
investigation of new technology shows the similarity 
between the invasively recorded intracranial pressure (ICP) 
and non-invasively recorded intracranial blood volume 
(IBV) pulse waves, slow waves and slow trends under 
intensive care unit (ICU) conditions. Also, the applicability 
of the non-invasive IBV slow wave monitoring technique 
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for long-term non-invasive cerebrovascular autoregulation 
monitoring is supported by theoretical and experimental 
studies.  
The paper also describes a new absolute ICP 
measurement method which does not need calibration. The 
new method is based on a two-insonation depth 
transcranial Doppler (TCD) technique for absolute ICP and 
external absolute pressure aPe comparison using the eye 
artery (EA) as a natural ‘‘scales’’. The clinical study shows 
that it is possible to measure ICP non-invasively without 
calibration of the system. 
Materials, methods and results  
1. State of the art of non-invasive ICP measurement 
The arterial blood pressure (ABP) and intracranial 
pressure (ICP) are both fundamental physiological 
parameters that must be monitored in brain injured patients 
in order to determine their physiological state. The most 
important characteristics of brain cerebrovascular function 
are cerebral blood flow autoregulation (CA), cerebrospinal 
compliance (CS), cerebral perfusion pressure (CPP), which 
are all dependent on ABP and ICP [27, 9, 26, 5]. It has 
been technically possible to measure ABP non-invasively 
since 1904 [11] after the invention of Nobel prize (1944) 
winner Joseph Erlanger. Why it is still impossible to 
measure absolute ICP non-invasively?  
There are several main problems limiting the ability to 
create a non-invasive ICP meter. The first problem is to 
find a physiological or biophysical characteristic of the 
cerebrospinal system that could be related to ICP, the 
parameters of which could be measured using non-invasive 
methods. These concepts for a non-invasive ICP 
measurement have been appearing since 1977 which have 
generated many patents, the authors of which attempt to 
find the objects or physiological characteristics of the 
cerebrospinal system that would be related to the ICP and 
monitor them non-invasively (Table 1) [31, 29, 2, 17, 3, 
10, 20, 19, 12, 22, 35, 14, 15, 4, 21, 34]. Most of the 
proposed monitoring technologies are based on use of 
ultrasound and are capable of monitoring physiological 
properties such as blood flow in: intracranial [2, 17] or 
intraocular vessels [29, 3, 10], pulsations of the cerebral 
ventricle [20, 19], brain tissue [12, 22], cranial bone 
diameter [35], dura matter thickness [14, 15], acoustic 
properties of the cranium [4] or skull bones [21]. 
The second problem is to define the relationship 
between non-invasively measured characteristics of the 
craniospinal system and absolute ICP which includes all 
the key known influential physiological and physical 
factors. Such a relationship could be expressed using the 
generic equation: 
,...)ABP,(,...)ICPABP,,(F)(EICP ttt Sx Δ+= , (1) 
where: EICP is the non-invasively measured ICP, Fx is a 
non-linear function which relates EICP and ICP and which 
depends on many influential factors including time, ABP, 
cerebrospinal compliance, the state of cerebral 
autoregulation, the state of a patient’s individual 
demographic factors (gender, age, etc.), ΔS is the 
systematic error which also depends on a series of 
influential factors.  
The third problem that must be solved in order to 
implement the non-invasive ICP monitoring is the question 
how to calibrate non-invasively and individually to the 
patient the absolute ICP meter? 
While exploring these problems and considering the 
work of J. Guiset [12], we have developed the ultrasonic 
time of flight technology for non-invasive intracranial 
blood volume monitoring [27, 31, 25].  
Our technology is based on the following experimental 
findings: 
- the acoustic properties of the brain parenchymal 
acoustic path are dependent upon the blood, cerebrospinal 
fluid and parenchyma tissue volume within this path; 
- these acoustic properties can be measured or 
monitored non-invasively and in real-time; 
- the measured values of ultrasound speed and 
attenuation across the intracranial acoustic path are 
correlated to the intracranial volume changes and waves 
which are the causes of the ICP changes and waves. 
Using this approach, a new information about the 
human cerebrovascular system can be obtained while 
measuring the dynamics of the acoustic properties of brain 
parenchyma [27, 25, 24]. These include: 
- the correlation coefficient between non-invasively 
measured slow waves (such as B waves) of the cerebral 
blood volume and the slow waves of the ABP is an 
indicator of the function of cerebral blood flow 
autoregulation; 
- the changes of brain compliance due to the 
pathological changes in intracranial component volumes 
influences the cerebral blood outflow. These cerebrospinal 
compliance changes can be determined by measuring the 
parameters of cerebral blood volume pulse waves. 
2. Non-invasive intracranial blood volume change 
monitoring method 
The cause of ICP fluctuations and ICP waves 
(ΔICP(t)) are intracraniospinal volume (V) changes ΔV(t) 
(Fig. 1) [18]. Fig. 1 shows the relationship between ICP, V, 
CSC, intracranial blood volume pulse waves ΔV(t) and 
ICP pulse waves ΔICP(t). Our aim was to create non-
invasive ultrasonic technology for monitoring the volume 
V changes and volume waves ΔV(t) in order to study the 
dynamics underlying ICP change. The dynamics of the 
craniospinal axis have not been studied before because of 
the lack of non-invasive volumetric monitoring 
technology.  
The non-invasive measurement of the changes of 
intracranial component volumes is based on the time-of-
flight for transmission of ultrasonic waves through a 
human head [27, 24]. As all intracranial components (brain 
tissue, cerebrospinal fluid, blood) have different acoustic 
properties (ultrasound speed, frequency dependent 
attenuation), changes of their relative content inside the 
acoustic path will influence the total acoustic 
characteristics of intracranial media and thus the monitored 
parameters of the ultrasonic signal as well [27, 24]. 
The results of mathematical simulations [27, 24] of 
ultrasound pulse propagation through the human brain 
show the linear relationship between changes in the time-  
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Fig. 1. Relationship between ICP, V, CSC, intracranial blood volume 
pulse waves ΔV(t) and ICP pulse waves ΔICP(t) 
of-flight of the ultrasound pulse with changes in a blood 
volume within the cerebral parenchyma. Because the 
intracranial blood volume changes are directly related to 
ICP and craniospinal compliance changes, it supports the 
use of the time-of-flight measurement to evaluate these 
physiogical parameters. 
2.1. Non-invasive monitoring of ICP trends  
The basic concept underlying the non-invasive 
monitoring of cerebral blood volume, ICP pulse waves, 
respiratory waves, slow waves and trend evaluation is 
outlined below [27, 25, 28]: 
- the intraventricular or supraventricular parenchymal 
acoustic path which crosses the human head is used as the 
volume under study (Fig 2). The parenchymal acoustic 
path mainly consists of parenchymal tissue, relatively 
small blood vessels (arterioles, venules and capillary 
vessels) and a small amount of cerebrospinal fluid (CSF) 
(Fig. 2). The parenchymal arterioles are those mainly 
responsible for cerebral blood flow autoregulation. The 
speed of ultrasound within the parenchymal acoustic path 
mainly depends on the blood volume inside this path. Also, 
the attenuation of ultrasound inside this path mainly 
depends on the volume of parenchymal tissue inside this 
path, 
- to measure the changes in ultrasound speed inside the 
parenchymal acoustic path, this path is insonated by 
broadband ultrasonic pulses and the time-of-flight 
measured, 
- to compensate for the the influences of the external 
tissue hemodynamics in real-time and in situ the same 
ultrasonic pulses and their echoes from internal surfaces of 
the skull are alse measured, 
- specially designed software is used to convert the 
measured data into both absolute and relative indices for 
ICP, CPP or into the status of cerebral blood flow 
autoregulation.  
This method is the only existing technology for non-
invasive monitoring of the volume dynamics of the 
cerebral parenchyma microvessels. 
The non-invasive ultrasonic Vittamed monitor (Fig.3) 
was designed and tested in several intensive care units 
(ICU). The display panels of the Vittamed monitor are 
shown in Fig. 4 a, b and c.  
 
 
 
Fig. 2. State of the art methodologies for non-invasive ICP measurement 
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Fig. 3. Innovative, non-invasive intracraniospinal slow, respiratory 
and pulse volumetric wave monitor (Vittamed 105) and 
cerebrovascular autoregulation monitor (Vittamed 505): a - 
Vittamed 105 front panel, b - Vittamed 505 front panel, c - 
Vittamed 105 and Vittamed 505 rear panel, d - typical position 
of mechanical frame affixed on the human head 
 
 
 
a 
 
 
b 
 
 
c 
Fig. 4. The display panels of the non-invasive Vittamed monitor: a - 
for pulse, respiratory wave and trend monitoring; b - for 
cerebrovascular autoregulation monitoring using slow 
intracranial wave methodology; c - for pulse wave shape 
analysis 
a 
b 
d 
c 
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The simultaneous invasive ICP monitoring (Camino or 
Codman) with the non-invasive Vittamed monitor was 
performed for ICU coma patients with severe closed head 
injuries. The clinical results of simultaneous ICP pulse 
wave monitoring and long - term trend monitoring 
(1h...3h) are illustrated in Fig. 5 a, b, c, d and e.  
The non-invasive ICP indices were calculated from the 
ultrasound time-of-flight data using linear conversion after 
the real-time and in situ compensation of the influence of 
the external tissue and skull bones on the measured time-
of-flight data.  In 18 head injured patients we demonstrated 
a linear relationship between the measured ultrasound 
speed in the cerebral parenchymal acoustic path and ICP. 
The test range was clinically relevant and covered a range 
from ICP = 0 mmHg up to ICP = 50 mmHg. This linear 
relationship covers the critical treatment level of ICP 
which is believed to be approximately 20 mmHg. 
2.2. The concept of cerebrovascular autoregulation 
non-invasive monitoring  
Slow waves of ICP are the consequence of slow 
variations of intracranial blood volume. The duration of 
slow B waves can vary between 30 s to 200 s [9].  
In the case of normal autoregulation, the correlation 
coefficient between ICP and BP r(ICP;ABP) is negative 
and opposite to that found with an impaired cerebral 
autoregulation (CA) which is has a positive correlation 
coefficient r(ICP;ABP) [35, 36]. Under optimal 
autoregulatory conditions, r(ICP;ABP) is close to –1.  With 
functioning autoregulation, an increase in CPP (within the 
physiological limits) is accompanied by constriction of the 
cerebral arterioles (active vasoconstriction), i.e. their 
diameter decreases in order to keep the cerebral blood flow 
stabilised. In the case of impaired cerebral autoregulation 
(CA), an increase in ABP is accompanied by passive 
dilatation of the cerebral arterioles, i. e. their diameter and 
blood flow rate increases with the a rise in CPP. Under 
worst case conditions for impaired CA the correlation 
between ICP and BP r(ICP; ABP) tends towards +1. 
For non-invasive monitoring, the invasive ICP slow 
wave monitor could be replaced by the non-invasive 
monitoring of the relative speed ΔC/C0 of ultrasound 
through a volume of brain parenchyma, which also reflects 
the slow variations of intracranial blood volume. Thus, the 
estimation of CA can be performed by calculating the 
correlation coefficient between slow ABP waves and also 
slow ΔC/C0 waves (as a measure of B-wave activity due to 
fluctuations in the cerebral blood volume). The same ABP 
waves were used for calculation of both invasive r(ICP; 
ABP) and non-invasive r(ΔC/C0; ABP) coefficients.  
The concept of non-invasive CA monitoring has been 
demonstrated experimentally in studies conducted in the 
ICU. Twelve severely head injured patients under different 
pathophysiological conditions were monitored invasively 
and non-invasively using invasive ICP monitoring 
(Codman or Camino), invasive ABP monitoring (Datex) 
and non-invasive monitoring (Vittamed). The distribution 
for ICP and ABP ranged from 3 to 80 mmHg and 35 to 140 
mmHg respectively. The average age of patients was 31.25 
years. The youngest and oldest patients were 21 and 64 
years old respectively. Fifty-five one hour sessions of 
invasive and non-invasive CA monitoring and 86 one hour 
sessions of ICP and ΔC/C0 simultaneous monitoring have 
been performed during clinical studies. We found that 40% 
of the total time of monitorings (86 hrs) the correlation 
coefficient between ΔC/C0 and ICP r(ΔC/C0; ICP) 
exceeded 0.9. About 80% of the total monitoring time 
r(ΔC/C0; ICP) was above 0.6. This indicates that invasive 
monitoring of ICP slow waves can be effectively replaced 
by non-invasive monitoring of the intracranial volume 
slow waves and that the correlation coefficient between 
ABP waves and the relative velocity change of ultrasound 
transmission r(ΔC/C0; ABP) can be reliably used for non-
invasive estimation of the status of CA. 
We also determined that the correlation coefficient 
r(ΔC/C0; ICP) exceeds 0.9 when the amplitude of CPP B 
waves is above 3 mmHg. Thus the threshold for reliable 
diagnosing of CA could be chosen to be close to 3 mmHg 
for slow waves in CPP, as as found in many 
pathophyiological cases, the amplitude of CPP slow waves  
are within the ranges of 3 to 30 mmHg. Furthermore, a 
minimum of a 3 mmHg amplitude CPP slow wave is 
typically found in infants as well. 
An example of a one-hour session of simultaneous 
invasive and non-invasive monitoring of slow waves and 
cerebrovascular autoregulation is illustrated in Fig. 6. It 
shows a good agreement between invasive and non-
invasive measurements r(ΔC/C0; ABP) ≅ r(ICP; ABP). The 
correlation coefficient r(ΔC/C0; ICP) between ΔC/C0 and 
ICP slow waves was close to +1,0 while the state of CA 
was changing from intact CA (r<0) to impaired CA (r>0) 
(Fig. 6). Key unique feature of the using non-invasive CA 
monitoring technology is that our method of the correlation 
coefficient analysis does not require calibration 
procedures. Moreover, this technique appears insensitive to 
any drift or the absolute magnitude of the non-invasively 
measured data. 
3. Ultrasonic method for absolute ICP 
measurement without calibration problem 
Existing non-invasive ICP measurement 
methodologies share a common problem of calibration into 
absolute (aICP) data. This problem is the main factor 
limiting the effective implementation of non-invasive aICP 
measurement systems into clinical practice [30]. 
The only reliable solution for non-invasive aICP 
measurement system calibration we have found is to 
calibrate aICP measurement by the direct comparison of 
aICP with an extracranially applied pressure aPe using a 
“physiological scales” methodology. The question is where 
are such “scales” suitable for aICP measurement in the 
human body?  
One option is to use intracranial arteries as natural ICP 
sensors. The ophthalmic artery (OA) is a unique vessel 
with both intracranial (OI) and extracranial segments (OE) 
with almost similar anatomy. The pressure balance 
between the two segments can be achieved when the 
absolute value of external pressure aPe applied to OE via 
the eye orbit, is equal to the aICP which affects the 
intracranial segment of OI [29].  When balanced aPe = 
aICP and the blood flow parameters in both OA segments  
(OE and OI) are almost equal and independent of: the 
absolute value of arterial blood pressure, hydrodynamic  
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Fig. 5. Simultaneous invasive and non-invasive of ICP pulse waves a monitoring: a - ICP=80 mmHg, b - ICP=60 mmHg, c - ICP=40 mmHg,  
d - ICP=20 mmHg and e - long – term 3 h monitoring .  
a b 
c d 
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Fig.6. One hour invasive and non-invasive monitoring data of 
cerebrovascular autoregulation 
resistance of the eye veins, the pressure inside the eye ball 
and the initial absolute value of the blood flow in both 
segments of the eye artery. Therefore, by designing a 
special two depth pulse wave transcranial Doppler device 
that can simultaneously measure both the intracranial (OI) 
and extracranial (OE) segments of the OA we have a 
technology that can identify this balance in the natural 
“physiological scales”. The absolute value of external 
pressure which needs to be applied to the orbit to effect 
this balance reflects the absolute ICP value.  
In order to validate the proposed aICP measurement 
method we conducted a clinical study of simultaneous 
invasive and non-invasive aICP measurements performed 
under neurosurgical ICU conditions. The main goal of the 
study was to determine the systematic error of the non-
invasive method compared with the invasive method. In 
order to minimize any systematic errors the simultaneous 
invasive (ICP Codman) and non-invasive aICP 
measurements (physiological sclales method) were 
performed as soon as possible after implantation of 
invasive ICP transducers.  The study population consisted 
of all closed severe traumatic brain injury patients, 57 male 
and 37 females with a mean age of 27.6 (18–70) years. All 
were implanted with invasive ICP transducers.  
The results of the clinical study are summarized in 
Fig.7. A Bland - Altman plot (Fig. 7) of the simultaneous 
invasive and non-invasive aICP measurements shows that 
the difference Δ=ICPi - ICPn between simultaneous 
invasive and non-invasive aICP data has a negligible 
systematic error 0.939 mmHg. This systematic error (solid 
line in Fig. 7) does not depend on aICP over the tested 
aICP range. This data is evidence that the proposed non-
invasive aICP measurement system does not need 
correction for systematic errors, e.g., does not need 
calibration. The random errors (Fig. 7) inherent with the 
clinical data (SD = 6.18 mmHg) are followed by both 
invasive and non-invasive measurement systems.  
The random error of the non-invasive aICP system is 
mainly due to the limited resolution and accuracy of the 
two depth TCD device. That is a new challenge for further 
development of the two depth TCD technology 
development [27].  
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Fig. 7. Bland - Altman plot (57 simultaneous invasive and non-invasive aICP measurements in ICU): mean value m = ICPi-ICPn = 0.939 mmHg, 
standard deviation SD=6.18 mmHg, solid line shows a negligible systematic error of the non-invasive aICP measurement system. 
 
Acoustical output and safety parameters 
The derated acoustic intensity of transcranial Doppler 
device was approximately 50 mW/cm2 at the depth of 38 
mm, the sample volume was 3 mm. 
The main technical parameters of Vittamed 105 pulse 
wave monitor and Vittamed 505 cerebrovascular 
autoregulation monitor are as follows: 
– Central frequency of the transmitted ultrasonic pulse 
spectrum is 1.5 MHz. 
– Duration of transmitted ultrasonic pulses is 800 ns at 
the  level of 0.5 of the envelope amplitude, and its 
repetition frequency is 1.0 kHz. 
– Acoustic output parameters are derated spatial peak, 
the temporal-average intensity ISPTA3 = 0.869 mW/cm2; 
derated spatial-peak, the pulse average intensity ISPPA3 = 
1.181 W/cm2 and the ultrasonic power WO = 25 mW. 
– Resolution of measured time-of-flight or ultrasound 
velocity relative values is 1.25E-6, and the bandwidth of 
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non-invasive intracranial pressure/volume pulse waves 
measuring channel is 12 Hz. 
– Power supply is AC 100 V - 240 V, 1.5A, 47Hz - 
63Hz. 
– The device meets the requirements of EN 60601-1, 
EN 60601-2-37 and EN 60601-1-2 standards. 
– An electrocardiographic channel is used to associate 
the pulse wave recording with the cardiac cycle. 
– When 10 intracranial pulse waves are averaged using 
the sampling frequency of 50 Hz, the time-of-flight 
measurement uncertainty is +/-0.07 ns (+/- standard 
deviation) in the frequency band from 0.6 Hz up to 5.0 Hz. 
Notable, when comparing the output power and the 
transmitted ultrasonic energy of the Vittamed 105 pulse 
wave monitor and the Vittamed 505 cerebrovascular 
autoregulation monitor with the existing transcranial 
Doppler devices (TCD), is the following: 
– The output acoustic power of the Vittamed monitors 
is less than the power of clinical TCD devices (e.g., DWL 
Multi Dop X4). 
– Duration of the output ultrasonic pulses of the 
Vittamed monitors is 5 times shorter and their repetition 
period is 12 times lower than they are, as compared, with 
clinical TCD devices. 
 
Table 1. Main patents of non-invasive ICP measurement methods 
Author and 
patent number, Year 
Object or characteristic related to 
ICP 
 
Method 
Guiset [14] 
FR Pat. 2318420 
1977 Acoustic properties of brain tissues Ultrasound pulse transmission through the intracranial media and signal time-of-flight measurement 
Allocca [23] 
US Pat. 4,204,547 
1980 
Blood flow in a jugular vein  
Occlusion of blood flow in a jugular vein and the electromagnetic 
measurement of the change of blood flow within the jugular vein 
upstream of the occlusion 
Rosenfeld et al. [24] 
US Pat. 4564022 1986 Electrical brain activity 
Measurement of the changes of electrical brain activity after the light 
stimulus into the eyes 
Kageyama [18] 
US Pat. 4,971,061 1990 
Dura matter thickness 
 
Amplitude measurement of ultrasound interference echoes reflected 
from dura matter  
Kageyama [17] 
US Pat. 4,984,567 1991 
Dura matter thickness 
 
Cepstrum analysis of ultrasound interference echoes reflected from 
dura matter 
Mick  [20] 
US Pat. 5,117,835 1992 Sound attenuation in skull bones 
Measurement of ultrasound attenuation in skull bones and signal 
spectrum analysis 
Ragauskas et al. [6] 
US Pat. 5,388,583 1995 
Acoustic properties of brain 
parenchyma tissue 
Ultrasound pulse transmission through the intracranial media and 
signal time-of-flight measurement  
Yost et al. [16] 
US Pat. 5,617,873 1997 Cranium diameter 
Phase measurement of ultrasound signal reflected from the  far side of 
the skull  
Paulat [22] 
WO 97/30630 1997 Electrical resistance of the skull Signal waveform analysis 
Bridger et al. [19] 
US Pat. 5,919,144 
 
1999 
Acoustic impedance and resonance 
characteristics of the cranium 
Low frequency acoustic signal transmission through the cranium and 
the application of the spectral analysis for a detected signal 
Alperin [8] 
US Pat. 5,993,398 
 
1999 
Arterial and venous blood flow and  
the cerebrospinal fluid flow Phase contrast magnetic resonance imaging 
Denninghoff [11] 
WO 99/65387 
 
1999 
Eye vessels and intraocular 
pressure 
Simultaneous measurement of the SrVO2 saturation in retinal vessels, 
intraocular pressure and cardiac cycle 
Ragauskas et al. [7] 
US Pat. 5,951,477 
1999 Blood flow in the eye artery Ultrasonic two depth Doppler blood flow measurement technique 
Madsen et al. [9] 
US Pat. 6,086,533 2000 
Blood flow in the intracranial 
vessels Ultrasonic Doppler blood flow measurement technique 
Borchert et al. [10] 
US Pat. 6,129,682 2000 
Parameters of an optic nerve of the 
eye  Optical coherence tomography  
Sinha [21] 
US Pat. 6,117,089 
 
2000 Stress level of skull bones 
Generating and detecting standing waves in the skull bones and the 
measurement of phase difference between the transmitted oscillatory 
signal and the received signal  
Michaeli [12,13] 
WO 0068467, US 
6,702,743  
2000, 
2004 Cerebral ventricle vibration Analysis of echo pulsogram  waves 
Mourad [15],  
US Pat. 6,875,176 2005 Brain tissue displacement Ultrasonic brain elasticity measurement 
 
Conclusions 
The comparative clinical studies outlined in this paper 
on the non-invasive ultrasonic Vittamed monitoring 
technology simultaneously with invasive ICP monitors 
conducted in the ICU show that: 
- it is possible to achieve measurement accuracy better 
than +/-2.0 mmHg for long term non-invasive ICP 
monitoring using our the time of flight methodology over a 
clinically relevant range of ICP values from 0 mmHg to 50 
mmHg and to achieve a high correlation r = 0.997 between 
invasively and non-invasively measured ICP data; 
- the non-invasive time-of-flight technology Vittamed 
can also be applied for continuous cerebrovascular 
autoregulation monitoring based on correlation monitoring 
between BP and non-invasive ICP slow waves. The high 
correlation between invasively and non-invasively 
measured ICP and intracranial blood volume slow wave 
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data has been demonstrated in these clinical studies 
(p>0.95, 87 hours of monitoring in 13 patients); 
- the amplitude and shape of non-invasively measured 
intracranial blood volume (IBV) pulse waves are also 
related to cerebrospinal compliance. 
The innovative “physiological scales” method 
described in this paper for measurement of absolute ICP by 
non-invasive two depth TCD measurement, is the only 
known method for non-ivasive measurement of absolute 
ICP without the need for individual patient to patient 
calibration.  
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R. Šliteris, V. Deksnys, J. Guzaitis, G. Lengvinas  
Žmogaus smegenų intrakranijinės biomechanikos neinvazinė 
stebėsena 
Reziumė 
Apžvelgiami inovatyvūs žmogaus smegenų neinvazinės fiziologinės 
stebėsenos metodai ir technologija. Metodai remiasi smegenų 
parenchimos akustinių savybių matavimu. Klinikiniai technologijos 
tyrimai parodė esant panašumo tarp invaziškai užregistruotų 
intrakranijinio slėgio bangų (ICP) ir neinvaziškai užregistruotų 
intrakranijinių kraujo tūrio pulsinių bangų (IBV), lėtų bangų ir lėtų 
trendų, gaunamų intensyvios terapijos metu. Be to, teoriškai ir 
eksperimentiškai ištirtas lėtų bangų matavimo siekiant įvertinti 
cerebrovaskuliarinės autoreguliacijos būseną tinkamumas. Aptartas 
absoliučiojo intrakranijinio slėgio (ICP) matavimo metodas, 
nereikalaujantis papildomo kalibravimo. 
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